Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Aquestive Therapeutics, Inc. $AQST Shares Sold by Squarepoint Ops LLC

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

8,069,373 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by BlackRock Inc.

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

AWM Investment Company Inc. Takes $1.98 Million Position in Aquestive Therapeutics, Inc. $AQST

Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET